<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Studies have shown that <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C (HCV) is associated with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e>) possibly due to <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> is a risk factor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Our objectives were to assess the relationship between HCV and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and inflammatory markers </plain></SENT>
<SENT sid="3" pm="."><plain>We used data from The Third National Health Nutrition and Examination Survey (NHANES-III) </plain></SENT>
<SENT sid="4" pm="."><plain>We excluded pregnant women, subjects with <z:mp ids='MP_0002055'>diabetes</z:mp>, those taking <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi>, and those diagnosed with concomitant <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>We analyzed the data controlling for demographic variables, body mass index, use of contraceptives, had <z:hpo ids='HP_0001369'>arthritis</z:hpo>, and had <z:hpo ids='HP_0001997'>gout</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Among the 10,383 subjects, 2.3% had HCV and 16.7% had <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> using the ATP III criteria </plain></SENT>
<SENT sid="7" pm="."><plain>After controlling for the confounders, HCV was not associated with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> but associated with HOMA <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and inflammatory marker ferritin </plain></SENT>
<SENT sid="8" pm="."><plain>Among subjects with both HCV and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, the adjusted HOMA insulin level was higher than those without HCV and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, the serum ferritin level was a strong predictor of HOMA <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>In clinical practice, serum ferritin can be obtained along with routine blood tests in any laboratory, and it has a potential to be a surrogate marker of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in people with HCV and <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
</text></document>